Daylight Closes $6 Million Seed Round Led by USV and 1kx
Daylight, a personalised on-chain behavioural recommendation platform, has closed a $6 million seed round led by Union Square Ventures (USV), with co-lead from 1kx and participation from Framework Ventures, Chapter One, and the co-founders of Zerion, Blockaid, and Yup. The round brings Daylight's total funding to $9 million to date, led by Union Square Ventures (USV), co-led by 1kx, with participation from Framework Ventures, Chapter One, and the co-founders of Zerion, Blockaid, and Yup. Daylight is said to be an ‘on-chain personalisation’ API that integrates with major wallets such as MetaMask and Coinbase Wallet, offering users advice on transactions such as airdrop pickups and NFT casting. The company says its API currently drives 5% of the trading addresses of its partner wallets, with 6 million active addresses receiving recommendations each month. daylight plans to add a major new trading category in Q4, and is hiring back-end engineers and auditors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Uniswap.com Domain Story Resurfaces After SBF Purchase Claim
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).